Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation approach ...

Medtronic's BrainSense aDBS personalizes Parkinson's therapy in real-time, minimizing manual adjustments for better symptom control. BrainSense Electrode Identifier speeds up initial DBS ...

The FDA approved the world’s first adaptive deep brain stimulator for the disease.

The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode identifier) for people with Parkinson's disease, Medtronic announced Monday. Like ...

After hours: March 11 at 7:50:26 PM EDT Loading Chart for MDT ...

The global motion stimulation therapy market is set for significant growth, with market projections estimating its value at USD 1.4 billion in 2024. Fueled by rapid technological integration in ...

Medtronic brought in revenues of $8.3bn for the quarter, up 2.5% from the same period in 2024. Image credit: Shutterstock / JHVEPhoto. Medtronic posted a strong profit for Q3 of fiscal year 2025, ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease.

Nanovis announced today that it sold certain nano surface technology assets and certain IP rights to Medtronic (NYSE: MDT) +. Columbia City, Indiana–based Nanovis said Medtronic acquired the ...

HYDERABAD Feb 25 (Reuters) - Medical device maker Medtronic (MDT.N), opens new tab is looking at options to modify its global manufacturing footprint as part of efforts to mitigate any impact of U ...